Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac
Investors Of Regeneron Pharmaceuticals Inc With Losses Are Encouraged To Contact As The Schall Law Firm Initiates A Probe Into Claims
05:00pm, Saturday, 13'th Jul 2024
LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac
LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac
Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings
05:41pm, Thursday, 11'th Jul 2024
Regeneron Pharmaceuticals, Inc. stock has increased over 20% in 2024, trading at $1,071 per share at the time of writing. Regeneron's valuation is high but arguably justified by potential growth, with
LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
07:28pm, Wednesday, 10'th Jul 2024
NEW YORK , July 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investo
Regeneron Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
03:27pm, Wednesday, 10'th Jul 2024
Investors can contact the law firm at no cost to learn more about recovering their losses
The Schall Law Firm Begins A Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Urges Investors With Losses To Reach Out
02:00pm, Wednesday, 10'th Jul 2024
LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac
Calls of the Day: Visa, Regeneron, Target, Spotify, Netflix, Starbucks and McDonald's
01:27pm, Wednesday, 10'th Jul 2024
The Investment Committee discuss the latest calls of the day.
LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
3 No-Brainer Stocks to Buy in July
08:00am, Monday, 08'th Jul 2024
Eli Lilly could be headed for a market capitalization above $1 trillion. Regeneron has overcome bumps and shows no signs of slowing down.
3 Pharma Stocks Already Ushering in the Next Biotech Boom
06:00am, Monday, 08'th Jul 2024
Let's get down to it: why should investors consider pharma stocks? Primarily, it comes down to the permanence of the underlying narrative.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
02:59pm, Sunday, 07'th Jul 2024
NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Suc
LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
